Drug Details
General Information of the Drug (ID: DR1885) | ||||
---|---|---|---|---|
Name |
Mesalazine
|
|||
Synonyms |
5-Aminosalicylic acid; mesalamine; Mesalazine; 5-Amino-2-hydroxybenzoic acid; 89-57-6; Asacol; Pentasa; Claversal; Canasa; 5-ASA; Salofalk; Rowasa; m-Aminosalicylic acid; Mesasal; Lialda; Benzoic acid, 5-amino-2-hydroxy-; Fisalamine; Lixacol; Apriso; p-Aminosalicylsaeure; Asacolitin; Mesalazina; Mesalazinum; sfRowasa; 5-amino-2-hydroxy-benzoic acid; Asacol HD; 5-Amino Salicylic Acid; SALICYLIC ACID, 5-AMINO-; MFCD00007877; 2-Hydroxy-5-aminobenzoic acid; 3-carboxy-4-hydroxyaniline; UNII-4Q81I59GXC; NSC 38877; MAX-002; MLS001424012; 4Q81I59GXC; CHEBI:6775; NSC-38877; CAS-89-57-6; NCGC00016344-03; Mesalazinum [Latin]; SMR000145728; DSSTox_CID_4506; DSSTox_RID_77435; DSSTox_GSID_24506; 5-Aminosalicylic acid, 99%; Mesalazina [Spanish]; p-Aminosalicylsaeure [German]; Mesavancol; Delzicol; Mesavance; Mezavant; Iialda; Mesalazine MMX; Mezavant XL; Mesalamine (USP); Pentasa (TN); Salofalk Granu-Stix; Apriso (TN); Asacol (TN); Canasa (TN); Lialda (TN); Rowasa (TN); 5-AS; CCRIS 7334; SR-01000763486; Mesalamine [USAN:USP]; EINECS 201-919-1; BRN 2090421; AI3-15564; HSDB 7512; AJG-501; SPD 476; SPD-476; SPD-480; Mesalamine (TN); Delzicol (TN); Sfrowasa (TN); Mesalazine [INN]; mesalamine (USAN); Mesalamine (Lialda); 5-aminosalicylic_acid; MD-0901; 5-Aminosalicyclic acid; 5-amino-salicylic acid; PubChem17623; Mesalamine; ; ; Mesalazine; ACMC-1BKFR; Prestwick0_001069; Prestwick1_001069; Prestwick2_001069; Prestwick3_001069; WLN: ZR DQ CVQ; Z-206; CHEMBL704; Mesalazine (JP17/INN); EC 201-919-1; cid_4075; Oprea1_847633; SCHEMBL31297; 3amino-6-hydroxybenzoic acid; BSPBio_001058; KBioGR_002425; KBioSS_002431; 4-14-00-02058 (Beilstein Handbook Reference); MLS000758287; 5-Aminosalicylic acid, 95%; 5-Aminosalicylic acid, tablet; ARONIS23914; BIDD:GT0811; 3-amino-6-hydroxybenzoic acid; SPBio_002969; BPBio1_001164; GTPL2700; ZINC1688; 5-Amino 2-hydroxy benzoic acid; DTXSID5024506; SCHEMBL18038934; 5-Aminosalicylic acid, >=99%; BDBM60918; KBio2_002425; KBio2_004993; KBio2_007561; KBio3_002904; cMAP_000045; HMS1571E20; HMS2051M21; HMS2090I09; HMS2098E20; HMS3393M21; HMS3649K15; HMS3651M15; HMS3715E20; Pharmakon1600-01505993; BCP05326; NSC38877; Tox21_110384; Tox21_201610; Tox21_303125; 5-?Aminosalicylic Acid (Mesalazine); ANW-39326; BBL013046; NSC759301; s1681; SBB052617; STK301678; AKOS000118959; Tox21_110384_1; AC-2764; BCP9000175; CCG-100829; DB00244; HS-0100; LS11426; MCULE-5752745805; NC00079; NSC-759301; NCGC00016344-01; NCGC00016344-02; NCGC00016344-04; NCGC00016344-05; NCGC00016344-07; NCGC00090934-01; NCGC00090934-02; NCGC00257142-01; NCGC00259159-01; 5-amino-2-hydroxobenzoic acid monohydrate; AK-72925; BP-13074; HY-15027; SY002854; 5-Aminosalicylic acid, analytical standard; ST4109571; A0317; AB00374979; AM20060091; FT-0619950; SW197303-4; 1764-EP2272825A2; 1764-EP2275420A1; C07138; D00377; M-7246; 24215-EP2289518A1; 24215-EP2295053A1; 24215-EP2295409A1; 24215-EP2314574A1; 24215-EP2314590A1; 90701-EP2371811A2; AB00374979-09; AB00374979-10; AB00374979_11; AB00374979_12; Q412479; 5-amino-2-hydroxybenzoic acid,5-Aminosalicylic acid; Q-201355; SR-01000763486-3; SR-01000763486-4; SR-01000763486-9; Z57127471; F1918-0003; Mesalazine, European Pharmacopoeia (EP) Reference Standard; Mesalamine, United States Pharmacopeia (USP) Reference Standard; Mesalamine, Pharmaceutical Secondary Standard; Certified Reference Material; Mesalazine for system suitability, European Pharmacopoeia (EP) Reference Standard; 51481-17-5
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Ulcerative colitis [ICD-11: DD71] | Approved | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C7H7NO3
|
|||
PubChem CID | ||||
Canonical SMILES |
C1=CC(=C(C=C1N)C(=O)O)O
|
|||
InChI |
1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
|
|||
InChIKey |
KBOPZPXVLCULAV-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 89-57-6
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Cryptolepine | Cryptolepis sinensis | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vivo Model | Healthy adult male Wistar rats (220-250 g) were used throughout the study. | |||||
Experimental
Result(s) |
Crocin and mesalazine produced protective effects on colon tissue via antioxidant and anti-inflammatory actions. In addition, a synergistic effect was observed between crocin and mesalazine in attenuating ulcerative colitis. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Prostaglandin G/H synthase 1 (COX-1) | Molecule Info | [3] | |
BioCyc | C20 prostanoid biosynthesis | Click to Show/Hide | ||
KEGG Pathway | Arachidonic acid metabolism | Click to Show/Hide | ||
2 | Metabolic pathways | |||
3 | Platelet activation | |||
4 | Serotonergic synapse | |||
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | Click to Show/Hide | ||
Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | Click to Show/Hide | ||
Pathwhiz Pathway | Arachidonic Acid Metabolism | Click to Show/Hide | ||
WikiPathways | Prostaglandin Synthesis and Regulation | Click to Show/Hide | ||
2 | Arachidonic acid metabolism | |||
3 | Phase 1 - Functionalization of compounds | |||
4 | Eicosanoid Synthesis | |||
5 | Selenium Micronutrient Network |